Hence, the package insert indicated that no modification is required for CP A and B. No study is available in CP C. Using afatinib in CP C patients may exacerbate liver failure, as 9.7% of patients experienced liver test abnormalities and 0.2% of those cases were fatal in regular usage of afatinib. This evidence concerns the gene NDUFAB1 and liver failure.